Published in Obesity and Diabetes Week, April 4th, 2005
The data presented by Dr. Marco Valgimigli showed that in this study a single high-dose bolus (SHDB) regimen of AGGRASTAT Injection (tirofiban hydrochloride) improved outcomes in diabetic patients undergoing percutaneous coronary intervention (PCI) when compared to placebo.
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Obesity and Diabetes Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.